Outlook of the infectious disease treatment market in China

According to the market research analysts at Technavio, the infectious disease treatment market in China is anticipated to grow steadily at a CAGR of more than 5% over the forecast period. With the increasing use of combination therapies, the infectious disease treatment market is anticipated to have a positive outlook in the coming years. Physicians are increasingly prescribing drugs that are a combination of anti-infective and corticosteroids. While anti-infectives help reduce the infection, the corticosteroids assist in reducing inflammation of the eye which is caused because of the infection. This helps in proving better efficacy as infections are always associated with inflammation of the conjunctival and corneal tissue, resulting in increased irritation. For instance, some common drugs used are Neo-Poly-Dex eye drops by Bausch & Lomb and Maxitrol by Alcon, which contain polymyxin B sulfates and neomycin and dexamethasone.

One of the significant trends spurring the growth of this market is the emergence of interferon-free therapies in the treatment of infectious diseases. At present, hepatitis C treatment relies on the administration of interferon-based therapies in combination with ribavirin. This treatment is associated with several adverse effects such as anemia and leukopenia. Therefore, researchers and vendors are focusing on developing DAAs with minimal side-effects compared to current treatment methods. Moreover, these therapies are intended to be all-oral regimens and once approved; they are anticipated to have a positive effect on the market. The launch of IFN-free therapies is expected to increase significantly the market sales of hepatitis drugs, which will bolster the growth of the infectious disease treatment market in China over the next four years.

Segmentation by application and analysis of the infectious disease treatment market

• Antibacterial drugs
• Antiviral drugs
• Antifungal drugs
• Antiparasitic drugs

During 2015, the antibacterial drugs segment dominated the market and accounted for a market share of more than 64% in terms of revenue. Tese drugs treat bacterial infections and are also used as bacterial chemotherapeutic agents in the treatment of cancer. The various classes of antibacterial drugs used to treat diseases are beta-lactams, macrolides, aminoglycosides, quinolones, phenicols, tetracyclines, folate antagonists, and other miscellaneous agents. However, the market share for this segment is anticipated to decline by 2020.

Competitive landscape and key vendors

The infectious disease treatment market in China is highly competitive owing to the presence of several well-established small and large providers. The market has tremendous growth opportunities which are resulting in a lot of new players exploring the market. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.

 Key vendors in this market are -

• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• Johnson & Johnson
• Merck
• Pfizer

Other prominent vendors analyzed in this report are Achaogen, Actelion, Adenovir Pharma, AstraZeneca, Bayer, Biocryst, Celsus Therapeutics, Cempra, Eleven Biotherapeutics, Exoxemis, Ferrer International, Griffin Discoveries, Hexima, InSite Vision, Insmed Incorporated, KaloBios Pharmaceuticals, Lytix Biopharma, Meiji Seika Pharma, Melinta Therapeutics, Moberg Pharma, NanoViricides, Nektar, NicOx, NovaBay, NovaBiotics, Ocular Therapeutix, Panoptes Pharma, Paratek Pharmaceuticals, Polichem, PTC Therapeutics, RedHill, Shire, Starpharma Holdings Limited, Sun Pharma, Symbiomix, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Topica Pharmaceuticals, Vertex Pharmaceuticals, and Viamet Pharmaceuticals.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the infectious disease treatment market in China?
• What are the key market trends impacting the growth of the infectious disease treatment market in China?
• What are the challenges to market growth?
• Who are the key vendors in infectious disease treatment market in China?
• What are the market opportunities and threats faced by the vendors in the infectious disease treatment market in China?
• Trending factors influencing the market shares of China.   
• What are the key outcomes of the five forces analysis of infectious disease treatment market in China?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Human Vaccine Market 2016-2020
• Global Antibody Drug Conjugates Market 2016-2020
• Global Immunotherapy Drugs Market 2016-2020
• Global Travel Vaccines Market 2015-2019